Table 3.

Base case cost-effectiveness analysis results

Year	Black ASMM				White ASMM

	PrEP costs ($)	Lifetime treatment costs averted ($)^a	Lifetime QALYs gained^a	ICER ($/QALY gained)	PrEP costs ($)	Lifetime treatment costs averted ($)^a	Lifetime QALYs gained^a	ICER ($/QALY gained)

1	8,916,437	5,822,546	54.19		9,490,205	1,769,431	16.47
2	8,906,283	6,617,560	61.59		9,231,334	1,700,886	15.83
3	8,776,044	6,283,405	58.48		8,966,204	1,403,644	13.06
4	8,539,999	6,623,654	61.65		8,707,172	2,068,190	19.25
5	8,283,667	6,330,134	58.91		8,458,090	1,945,689	18.11
6	8,031,371	6,387,490	59.45		8,231,114	1,564,107	14.56
7	7,801,862	6,163,517	57.36		7,984,423	1,536,891	14.30
8	7,589,310	6,460,415	60.13		7,759,780	1,371,048	12.76
9	7,363,724	6,131,474	57.06		7,526,922	1,991,485	18.53
10	7,149,336	5,393,177	50.19		7,305,548	1,443,397	13.43
10-y cumulative	81,358,034	62,213,372	579.01	33,064	83,660,791	16,794,768	156.31	427,788

ASMM = adolescent sexual minority males; ICER = incremental cost-effectiveness ratio; PrEP = pre-exposure prophylaxis; QALY = quality-adjusted life years.

Costs averted and QALYs gained were discounted to present value at a 3% rate.